Who are Oxybuprocaine SDU's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propofol/Lidocaine, Suzetrigine (SUZ), Exparel/bupivacaine mixture, Control (bupivacaine), Remifentanil+Lidocaine, Dexamethasone+ Bupivacaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxybuprocaine-sdu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oxybuprocaine SDU — Competitive Intelligence Brief

Oxybuprocaine SDU (Oxybuprocaine SDU) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Ophthalmology.

phase 3 Local anesthetic Voltage-gated sodium channels Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Oxybuprocaine SDU (Oxybuprocaine SDU) — Medical University of Vienna. Oxybuprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxybuprocaine SDU TARGET	Oxybuprocaine SDU	Medical University of Vienna	phase 3	Local anesthetic	Voltage-gated sodium channels
Propofol/Lidocaine	Propofol/Lidocaine	NYU Langone Health	marketed	Intravenous anesthetic combination	GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
Suzetrigine (SUZ)	Suzetrigine (SUZ)	Vertex Pharmaceuticals Incorporated	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Control (bupivacaine)	Control (bupivacaine)	Kasr El Aini Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Dexamethasone+ Bupivacaine	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

University of California, San Diego · 3 drugs in this class
Durect · 3 drugs in this class
Pacira Pharmaceuticals, Inc · 3 drugs in this class
Wake Forest University Health Sciences · 3 drugs in this class
Medical University of Vienna · 3 drugs in this class
Imperial College London · 2 drugs in this class
Hvidovre University Hospital · 2 drugs in this class
Innocoll · 2 drugs in this class
George Washington University · 2 drugs in this class
Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxybuprocaine SDU — Competitive Intelligence Brief. https://druglandscape.com/ci/oxybuprocaine-sdu. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab